ES2155510T3 - Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion. - Google Patents

Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Info

Publication number
ES2155510T3
ES2155510T3 ES95890132T ES95890132T ES2155510T3 ES 2155510 T3 ES2155510 T3 ES 2155510T3 ES 95890132 T ES95890132 T ES 95890132T ES 95890132 T ES95890132 T ES 95890132T ES 2155510 T3 ES2155510 T3 ES 2155510T3
Authority
ES
Spain
Prior art keywords
protein
procedure
immunization against
preparation
against infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95890132T
Other languages
English (en)
Inventor
Franz Xaver Prof Dr Heinz
Steven Dr Allison
Christian Doz Dr Mandl
Christian Prof Dr Kunz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2155510T3 publication Critical patent/ES2155510T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION DESCRIBE UNA VACUNA PARA INMUNIZACION CONTRA INFECCIONES DE VIRUS TBE, ABARCANDO PARTICULAS SUBVIRALES, NO INFECCIOSAS, QUE ABARCAN LA PROTEINA E Y EVENTUALMENTE PROTEINA PRM/M, SU VACUNA, ABARCANDO UN ACIDO NUCLEICO, QUE PARA LA PROTEINA E Y PROTEINA PRM/M SE DERIVA A PARTIR DEL VIRUS TBE, DONDE LA PROTEINA E SE ENCUENTRA PRESENTE O SE CODIFICA AL MENOS EN FORMA NATIVA ESENCIALMENTE COMPLETA.
ES95890132T 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion. Expired - Lifetime ES2155510T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung

Publications (1)

Publication Number Publication Date
ES2155510T3 true ES2155510T3 (es) 2001-05-16

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98107383T Expired - Lifetime ES2165109T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.
ES95890132T Expired - Lifetime ES2155510T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98107383T Expired - Lifetime ES2165109T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.

Country Status (9)

Country Link
EP (2) EP0869184B1 (es)
AT (2) ATE206459T1 (es)
CZ (1) CZ282927B6 (es)
DE (2) DE59508988D1 (es)
DK (2) DK0869184T3 (es)
ES (2) ES2165109T3 (es)
FI (2) FI117974B (es)
HU (2) HU219503B (es)
RU (1) RU2150294C1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316796T1 (de) * 1997-11-20 2006-02-15 Us Army Medical Res And Materi Dna impfstoffe gegen zecken-flavivieren
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284791B1 (de) * 1987-03-20 1995-05-03 IMMUNO Aktiengesellschaft DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus

Also Published As

Publication number Publication date
HUT72395A (en) 1996-04-29
EP0869184A3 (de) 1999-05-12
RU2150294C1 (ru) 2000-06-10
DK0869184T3 (da) 2001-12-17
ATE206459T1 (de) 2001-10-15
CZ282927B6 (cs) 1997-11-12
HU9501832D0 (en) 1995-08-28
FI953371A (fi) 1996-01-09
CZ176995A3 (en) 1996-01-17
EP0869184A2 (de) 1998-10-07
EP0691404B1 (de) 2001-01-24
ATE198909T1 (de) 2001-02-15
HU219503B (hu) 2001-04-28
EP0691404A3 (de) 1997-11-12
DK0691404T3 (da) 2001-03-19
FI953371A0 (fi) 1995-07-07
ES2165109T3 (es) 2002-03-01
EP0691404A2 (de) 1996-01-10
EP0869184B1 (de) 2001-10-04
HU9903233D0 (en) 1999-11-29
HU224199B1 (hu) 2005-06-28
DE59508988D1 (de) 2001-03-01
FI20070041A (fi) 2007-01-17
DE59509667D1 (de) 2001-11-08
FI118222B (fi) 2007-08-31
FI117974B (fi) 2007-05-15

Similar Documents

Publication Publication Date Title
ATE350057T1 (de) Impfstoffzusammesetzung
ATE542829T1 (de) Impfstoff
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
NO20015074D0 (no) Nye sammensetninger
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
AU6365301A (en) Vaccine
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
WO2003049765A3 (en) Enveloped virus vaccine and method for production
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
EA200301151A1 (ru) Вакцина против натуральной оспы
AR027443A1 (es) MUTANTES DE EHV gM-NEGATIVOS
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
MX9401384A (es) Uso de vacunas anti-helminticas en el control de la enfermedad por parasitos asociada con la perdidade la inmunidad natural.
BR0013574A (pt) Antìgeno vacina de moraxella
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
TH18188A (th) วัคซีนสำหรับป้องกันโรคทางเดินหายใจและช่องทางสืบพันธ์ของสุกร

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 691404

Country of ref document: ES